BioCentury
ARTICLE | Clinical News

Lurbinectedin: Phase III started

August 8, 2016 7:00 AM UTC

PharmaMar began the open-label, international Phase III ATLANTIS trial to compare PM1183 plus doxorubicin vs. topotecan or cyclophosphamide plus doxorubicin and vincristine in 600 patients with SCLC w...